Evidence map›Paper›PMID 42297568›Full record

Trial reportObesity (Silver Spring, Md.)2026

SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.

Martin K Rutter, Julie Mount, J Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding and 5 more

Registry-linked trialAbstract readPragmatic Clinical TrialRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT07247084. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07247084 phase4recruiting

A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting

Ran2025Enrolled3,000Registered outcomes17Posted comparisons0ConditionsObesityArmsStandard of care, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Martin K RutterDivision of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Julie MountEli Lilly and Company, Basingstoke, UK.
J Martin GibsonDivision of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Joanne WebbEli Lilly and Company, Basingstoke, UK.
Cheryl MarlerEli Lilly and Company, Indianapolis, Indiana, USA.
Catherine ReedEli Lilly and Company, Basingstoke, UK.
Mugdha GoreEli Lilly and Company, Indianapolis, Indiana, USA.
Wenyu YeEli Lilly and Company, Indianapolis, Indiana, USA.
Elisa Gomez ValderasEli Lilly and Company, Indianapolis, Indiana, USA.
John WildingDepartment of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
Naveed SattarSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0002-1604-2593
Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester, UK.
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester, UK.
Richard HaynesClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Rachel L BatterhamEli Lilly and Company, Basingstoke, UK.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

objectiveSURMOUNT-REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard-of-care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m

methodsA 5-year, phase 4, multicenter, open-label, pragmatic randomized clinical trial is enabled through access to participants' integrated electronic healthcare record data. The study will enroll approximately 3000 participants from Greater Manchester, UK, who are randomly assigned in a 1:1 ratio to receive either tirzepatide and SoC or SoC alone.

resultsThe primary endpoint is the percent change in body weight from baseline to Month 24, with the time to onset of type 2 diabetes to Month 60 being the key secondary endpoint. Additional endpoints include the impact of tirzepatide versus SoC on obesity-related complications, health-related quality of life, healthcare resource utilization, productivity, employment, and sickness-related absences.

conclusionsSURMOUNT-REAL UK employs a novel study design to evaluate real-world health outcomes and potential long-term benefits for both participants and the healthcare system associated with the delivery of pharmacological obesity treatment at a population level. The study is intended to generate critical evidence to support informed decision-making in obesity management, clinical guideline development, and healthcare policy.

trial registrationClinicalTrials.gov identifier: NCT07247084.

Indexed as

Anti-Obesity AgentsObesityTirzepatideAdultBody Mass IndexDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedPrimary Health CareQuality of LifeTreatment OutcomeUnited KingdomAnti-Obesity AgentsTirzepatideelectronic health recordsobesitypragmatic trialprimary caretype 2 diabetes incidence

Identifiers

PMID42297568
PMCPMC13716189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.